Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2012. The document serves as a notification of a transaction involving a Non-Executive Director's interest in the company's American Depositary Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific director transaction notification and does not contain financial performance data.
Material Changes
The material change reported is a purchase of 10,000 ADSs by Non-Executive Director Ms. J Lewent on May 7, 2012, at a price of $46.5637 per ADS. No other material changes to the company's operations or financial position are disclosed in this document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly adheres to the disclosure requirements for director transactions under Disclosure Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: May 7, 2012
- Director Involved: Ms. J Lewent (Non-Executive Director)
- Transaction Type: Purchase of 10,000 ADSs
- Price per ADS: $46.5637
- Notification Date: May 8, 2012